Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR2 | O60603 | 1/20 | 0.54 |
| ▸ | NMT2 | O60551 | 3/20 | 0.54 |
| ▸ | NMT1 | P30419 | 3/20 | 0.54 |
| ▸ | NPY4R | P50391 | 7/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 6/20 | 0.50 |
| ▸ | NPY1R | P25929 | 5/20 | 0.50 |
| ▸ | NPY2R | P49146 | 3/20 | 0.50 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.44 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.44 |
| ▸ | FURIN | P09958 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16509060 | 0.96 | NPY4R (0.53) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL15185866 | 0.95 | NMT1 (0.60) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL16509056 | 0.94 | NPY4R (0.52) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL16509019 | 0.92 | NPY4R (0.56) | NPY4RNPY5RNPY1RNPY2R | |
| SCHEMBL16507758 | 0.92 | NPY4R (0.55) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL16976140 | 0.92 | NPY4R (0.58) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL16976101 | 0.92 | NPY4R (0.58) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL16976139 | 0.92 | NPY4R (0.58) | TLR2NMT2NMT1NPY4RNPY5R | |
| SCHEMBL16509114 | 0.91 | GLP1R (0.48) | TLR2NMT2NMT1 | |
| SCHEMBL16508995 | 0.91 | NPY4R (0.59) | TLR2NMT2NMT1NPY4RNPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | ANCHOR THERAPEUTICS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301087-A1 | CRF1 RECEPTOR COMPOUNDS | CRHR1, CRH, CRHR2 | TLR2 934/4885NMT2 4711/4885NMT1 4371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.